Evaluation of in-Hospital NT-ProBNP Changes in Heart Failure Patients to Identify the Six-Month Clinical Response Following Cardiac Resynchronization Therapy
N-terminal pro β-type natriuretic peptide (NT-proBNP) is a valuable marker for monitoring the response to treatment in patients with heart failure. Based on the clinically observed improvement of heart failure symptoms early after cardiac resynchronization therapy (CRT), we sought to investigate whether CRT induce any significant reduction in the plasma level of NT-proBNP in three days after implantation and whether it is correlated with patients' response at six months. In this prospective study, 21 consecutive patients with severe heart failure (New York Heart Association class 3.19±0.40) who underwent CRT were enrolled. Being alive, no hospitalization due to decompensated heart failure, and improvement of at least one NYHA functional class at six months were classified as clinical responsiveness. The plasma level of NT-proBNP was measured before, three days, and six months after CRT. Clinical evaluation, echocardiographic study, and six-minute walking test were performed before and six months after the procedure. At six months' follow-up, 16 (76.2%) patients were responders. The plasma level of NT-proBNP at three days after CRT increased almost equally in both responder and non-responder groups of patients (∆NT-proBNP was 40.94±135.74 vs. 54.80±88.98); however, at six months' follow-up, the NT-proBNP changes statistically differed across the two groups of patients (P=0.005). According to our findings, NT-proBNP percent deviation from baseline to three days after CRT appears to be not correlated with the patients' clinical response after six months, which was incongruent to the patients' clinical improvement after CRT.
Asareh AR, Alasti M, Beygi SH, Fayazi S: Effect of discharge education on quality of life and hospital readmission in patients with heart failure: Is it effective? J Tehran Univ Heart Center 2009;3(1):17-20.
Wang RUX, Guo TAO, Li XR: Bnp/nt-probnp and cardiac pacing. A review. Pacing Clin Electrophysiol 2009;32(6):794-9.
Pitzalis MV, Iacoviello M, Di Serio F, Romito R, Guida P, De Tommasi E, Luzzi G, Anaclerio M, Varraso L, Forleo C, Pansini N. Prognostic value of brain natriuretic peptide in the management of patients receiving cardiac resynchronization therapy. Eur J Heart Fail 2006;8(5):509-14.
Jessup M, Brozena S. Medical progress: Heart failure. N Engl J Med 2003;348(20):2007-17.
Khand A, Gemmel I, Clark AL, Cleland JG. Is the prognosis of heart failure improving? J Am Coll Cardiol 2000;36(7):2284-86.
Kazemi SA, Bozorgi A, Davoudi GHR, Sadeghian S, Yamini Sharif A, Moezi ALI, Alenabi T, Khoushnevis M: Comparison of benefits from cardiac resynchronization therapy between patients with ischemic cardiomyopathyand patients with idiopathic dilated cardiomyopathy. J Tehran Univ Heart Center 2009;4(2):115-8.
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. Cardiac resynchronizationheart failure (care-hf) study investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352(15):1539-49.
Glick A, Michowitz Y, Keren G, George J. Neurohormonal and inflammatory markers as predictors of short-term outcome in patients with heart failure and cardiac resynchronization therapy. Isr Med Assoc J 2006;8(6):391-5.
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG. Comparison of medical therapy, pacing, and defibrillation in heart failure (companion) investigators. Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350(21):2140-50.
Berger R, Shankar A, Fruhwald F, Fahrleitner-Pammer A, Freemantle N, Tavazzi L, Cleland JGF, Pacher R. Relationships between cardiac resynchronization therapy and n-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: An analysis from the cardiac resynchronization in heart failure (care-hf) study. Eur Heart J 2009;30(17):2109-16.
Abraham WT, Young JB, León AR, Adler S, Bank AJ, Hall SA, Lieberman R, Liem LB, O'Connell JB, Schroeder JS, Wheelan KR; Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 2004;110(18):2864-8.
Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, Boehmer JP, Higginbotham MB, De Marco T, Foster E, Yong PG. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003;42(8):1454-9.
Magne J, Dubois M, Champagne J, Dumesnil JG, Pibarot P, Philippon F, O'Hara G, Sénéchal M. Usefulness of ntpro bnp monitoring to identify echocardiographic responders following cardiac resynchronization therapy. Cardiovascular Ultrasound 2009;7(1):39-48.
Piepoli MF, Villani GQ, Corrà U, Aschieri D, Rusticali G. Time course of effects of cardiac resynchronization therapy in chronic heart failure: Benefits in patients with preserved exercise capacity. Pacing Clin Electrophysiol 2008;31(6):701-8.
Pfister R, Schneider CA: Natriuretic peptides bnp and ntpro- bnp. Established laboratory markers in clinical practice or just perspectives? Clin Chim Acta 2004;349(1-2):25-38.
Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The amino-terminal portion of pro-brain natriuretic peptide (pro-bnp) circulates in human plasma. Biochem Biophys Res Commun 1995;214(3):1175-83.
Troughton RW, Frampton CM, Yandle TG, Espine EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (n-bnp) concentrations. Lancet 2000;355(9210):1126-30. 18. Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, Dargie HJ. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999;138(6):1126-32.
James KB, Troughton RW, Feldschuh J, Soltis D, Thomas D, Fouad-Tarazi F. Blood volume and brain natriuretic peptide in congestive heart failure: A pilot study. Am Heart J 2005;150(5):984-9.
De Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996;31(1):7-18.
Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J ClinEndocrinol Metab 1993;76(1):91-6.
Kubanek M, Malek I, Bytesnik J, Fridl P, Riedlbauchova L, Karasova L, Lanska V, Kautzner J. Decrease in plasma b-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months. Eur J Heart Fai 2006;8(8):832-40.
Cazeau S, Ritter P, Lazarus A, Gras D, Backdach H, Mundler O, Mugica J. Multisite pacing for end stage heart failure: Early experience. Pacing and Clinical Electrophysiology 1996;19(11):1748-57.
Blanc JJ, Etienne Y, Gilard M, Mansourati J, Munier S, Boschat J, Benditt DG, Lurie KG. Evaluation of different ventricular pacing sites in patients with severe heart failure: Results of an acute hemodynamic study. Circulation 1997;96(10):3273-7.
Leclercq C, Cazeau S, Le Breton H, Ritter P, Mabo P, Gras D, Pavin D, Lazarus A, Daubert JC. Acute hemodynamic effects of biventricular ddd pacing in patients with endstage heart failure. J Am Coll Cardiol 1998;32(7):1825-31.
Auricchio A, Stellbrink C, Block M, Sack S, Vogt J, Bakker P, Klein H, Kramer A, Ding J, Salo R, Tockman B, Pochet T, Spinelli J. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. Circulation 1999;99(23):2993-3001.
Butter C, Auricchio A, Stellbrink C, Fleck E, Ding J, Yu Y, Huvelle E, Spinelli J, Pacing Therapy for Chronic Heart Failure II Study Group. Effect of resynchronization therapy stimulation site on the systolic function of heart failure patients. Circulation 2001;104(25):3026-9.
Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110(15):2168-74.
Di Somma S, Magrini L, Pittoni V, Marino R, Mastrantuono A, Ferri E, Ballarino P, Semplicini A, Bertazzoni G, Carpinteri G, Mulè P, Pazzaglia M, Shah K, Maisel A, Clopton P. In-hospital percentage bnp reduction is highly predictive for adverse events in patients admitted for acute heart failure: The italian red study. Critical Care 2010;14(3):R116.
Villa G, Padeletti L, Lazzeri C, Salvi S, Michelucgi A, Fronzaroli C, Porciani C, Mezzani A, Franchi F. Plasma levels of natriuretic peptides during ventricular pacing in patients with a dual chamber pacemaker. Pacing Clin Electrophysiol 1994;17(5):953-8.
Noll B, G ◌ِke B, Simon B, Maisch B. Cardiac natriuretic peptide hormones during artificial cardiac pacemaker stimulation and left heart catheterization. Clin Investig 1992;70(12):1057-60.
Madaric J, Vanderheyden M, Van Laethem C, Verhamme K, Feys A, Goethals M, Verstreken S, Geelen P, PenickaM, De Bruyne B. Early and late effects of cardiacresynchronization therapy on exercise-induced mitral regurgitation: Relationship with left ventricular dyssynchrony, remodelling and cardiopulmonary performance. Eur Heart J 2007;28(17):2134-41.
El Saed A, Voigt A, Shalaby A: Usefulness of brain natriuretic peptide level at implant in predicting mortality in patients with advanced but stable heart failure receivingcardiac resynchronization therapy. Clin Cardiol 2009;32(11):E33-8.
Lellouche N, De Diego C, Cesario DA, Vaseghi M, Horowitz BN, Mahajan A, Wiener I, Boyle NG, Fonarow GC, Shivkumar K. Usefulness of preimplantation b-type natriuretic peptide level for predicting response to cardiac resynchronization therapy. Am J Cardiol 2007;99(2):242-6.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.